- Knowledge center
RNA sequencing is state-of-the-art technology for unbiased, specific and sensitive quantification of coding and non-coding RNA transcripts. In addition to classic RNA abundance analysis, Biogazelle also exploits the structural information encoded in the transcriptome, such as splice variants, gene fusions, mutations, and RNA editing events.
Digital PCR (dPCR) enables nucleic acid quantification with superior accuracy, precision and relative sensitivity. Biogazelle is at the forefront of digital PCR-based research. Over the years, we have performed various dPCR projects for our customers, both in research and clinical trial setting.
It is well known that qPCR based approaches for gene expression studies have excellent sensitivity, specificity, linear dynamic range of quantification, next to a high level of flexibility. As expert qPCR service provider, Biogazelle supports any qPCR-based application, using either off-the-shelf qPCR assays or expertly designed and validated custom primers.
Cancer gene mutations are increasingly being used as biomarkers for diagnosis, prognosis, treatment stratification, and monitoring of therapy response. At Biogazelle digital PCR is used for detection of specific cancer gene mutations in DNA or RNA, whereas RNA sequencing technology is used to study transcriptome wide gene mutations in RNA.
Fusion transcripts are hallmarks and common drivers in cancer, making them ideal targets for diagnostic and therapeutic purposes. At Biogazelle RNA sequencing technology is used to study transcriptome wide fusion genes in RNA, whereas digital PCR is used for detection of known fusion genes in DNA or RNA.